OpGen Announces Closing of $3.38 Million Registered Direct Offering
03 oct. 2022 16h20 HE
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
03 oct. 2022 07h30 HE
|
OpGen, Inc.
Prospective multicenter trial for the Unyvero UTI Panel has successfully completed enrollment of patient samplesUrine samples have been collected from over 1,800 patients at 4 U.S. clinical trial...
OpGen Announces $3.38 Million Registered Direct Offering
30 sept. 2022 08h38 HE
|
OpGen, Inc.
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform
20 sept. 2022 07h30 HE
|
OpGen, Inc.
FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low and middle income countries (LMICs)Initial project focuses on...
OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global...
Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement
31 août 2022 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory
25 août 2022 07h30 HE
|
OpGen, Inc.
Expanding services and offerings to the infectious disease community throughout the U.S. provides revenue growth opportunityServices at launch include rapid turnaround sequencing of clinical isolates,...
OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update
11 août 2022 16h15 HE
|
OpGen, Inc.
Total Q2 2022 revenues of $1.0 million with product sales a key growth driverFirst two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022Requested additional 180-day...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time
28 juil. 2022 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven
26 juil. 2022 07h30 HE
|
OpGen, Inc.
Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility testing (wgsAST)Ares plans to strategically expand...